BenevolentAI
ben a potent antagonist developed to relieve in and provide rapid itch resolution atopic dermatitis ben is a inhibitor targeting and receptors the receptors were as part of an effort to mediators of both itch and in in using our molecular design we were able to design a inhibitor equipotent against the receptors ben is expected to treat atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization in addition to inhibiting and mediated dermal in ben will target mild moderate and severe atopic dermatitis patients addressing unmet need in the treatment of mild to moderate atopic dermatitis as a steroid sparing alternative and in more severe patients undergoing treatment with that require add on treatment | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
43 of 74
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io